Edition:
United Kingdom

Allergan plc (AGN.N)

AGN.N on New York Stock Exchange

163.27USD
8:28pm GMT
Change (% chg)

$-0.60 (-0.37%)
Prev Close
$163.87
Open
$164.01
Day's High
$164.83
Day's Low
$162.65
Volume
273,014
Avg. Vol
481,868
52-wk High
$197.00
52-wk Low
$142.83

Select another date:

Tue, Oct 30 2018

Photo

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

Allergan says offers undervalue business units for sale, shares fall

Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

UPDATE 3-Allergan says offers undervalue business units for sale, shares fall

Oct 30 Allergan Plc on Tuesday expressed disappointment in early offers from potential buyers for business units it has been trying to sell, and its shares fell more than 6 percent.

Allergan CEO disappointed with early buyer interest in business units

Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

Allergan CEO disappointed with early buyer interest in business units

Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

Allergan CEO disappointed with early buyer interest in business units

Oct 30 Allergan Plc's Chief Executive Officer Brent Saunders said on Tuesday early buyer interest in its women's health and infectious diseases business units was below the price of what he believes the businesses are valued.

Botox-maker Allergan's revenue drops 3 pct

Oct 30 Allergan Plc reported a 3 percent drop in quarterly revenue on Tuesday, as its faces increasing competition for its Alzheimer's treatment Namenda and other branded drugs.

Allergan says revenue from aesthetics unit may double by 2025

NEW YORK Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

CORRECTED-UPDATE 1-Allergan says revenue from aesthetics unit may double by 2025

NEW YORK, Sept 14 Allergan Plc said revenue from its medical aesthetics business could double by 2025, even as it faces increasing competition for its blockbuster wrinkle treatment, Botox.

UPDATE 1-FDA rejects Allergan's Esmya fibroid treatment

Aug 21 Allergan Plc said on Tuesday U.S. health regulators had declined to approve Esmya, its treatment for abnormal uterine bleeding in women with uterine fibroids, requesting more information and citing safety issues outside the United States.

Select another date: